Freeline Therapeutics pioneers gene therapies for chronic illnesses

JACKSON, Tenn. — Freeline Therapeutics is at the forefront of developing groundbreaking gene therapies for chronic diseases.

By introducing functional genes into liver cells, they aim for long-lasting treatment effects.

Their leading project, FLT201, targets Gaucher Disease Type 1.

Michael Parini, with extensive leadership in bio-pharma and bio-tech, shares more.

“We do see a tremendous opportunity to take the important work that we’re doing in Gaucher and use it to come up with a potential life changing medicine for this group of patients in Parkinson’s who have the GB8 defect,” said Parini.

This approach not only offers hope for symptomatic relief but also aims to alter disease progression, showcasing gene therapy’s potential to revolutionize treatment paradigms across different disorders.

For more local news click here.